Field diagnoses of small public companies, from the outside
PetMed Express carries 1-800-PetMeds on its books as a $375,000 intangible asset. Its own filings price what happened around it: the advertising discipline that bought a new customer for $42 in 2011 now pays $81, the yearly haul of new customers fell from 645,000 to 266,000, and the buyers went to pharmacies that ship themselves. Here is the gap, measured.
What this is: a marketing and positioning diagnosis of a public company, built entirely from the outside: their SEC filings and open demand signals. We picked PetMed Express because it is the cleanest public case we know of a business that kept paying full price for attention while the buyers who used to answer moved somewhere else. Most private companies live this exact story with no filings to show it. What this is not: investment research. We say nothing here about the stock, and you should draw no conclusion about it from anything below.
PetMed Express invented a category. In 1996 it began selling pet medications directly to owners, over a toll-free number, against the near-universal practice of buying whatever the vet handed you. The pitch was price. It worked for two decades: the company was profitable every single year from fiscal 2010 through fiscal 2023, and in fiscal 2019 it earned $37.7 million on $283 million in sales.
Across seventeen straight years the company never stopped paying for reach: its advertising expense stayed between $17.7 million and $30.6 million every single year. What changed is what the money buys. PetMed's own annual reports disclose a metric most companies would never publish: total advertising cost divided by new customers acquired. In fiscal 2011 that number was $42, and 645,000 new customers arrived. In fiscal 2026 it was $81, and 266,000 arrived. Same discipline, same category, twice the price, two-fifths of the volume. Fiscal 2026 closed with sales of $179 million, down 42% from the fiscal 2021 peak, and a net loss of $57.3 million.
Here is the part that makes this a marketing story rather than a retail story. The demand did not shrink. Americans search "pet pharmacy" more than they did five years ago, and the brand itself is still the single most-searched refinement of "pet meds" in the country. By every public signal we can capture, the demand changed address. It moved into Chewy's autoship, the vet's own portal, and the pharmacy counters at Costco, Walmart, and Publix. PetMed kept buying tickets to a channel its buyers were leaving, at auction prices set by the companies they were leaving for.
The numbers below are from PetMed's own filings, fiscal years ending in March. The acquisition-cost line is their own published metric.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Net sales, $M | 309.2 | 273.4 | 256.9 | 274.1 | 227.0 | 179.0 |
| Net income (loss), $M | 30.6 | 18.7 | 5.1 | (7.5) | (6.3) | (57.3) |
| Advertising expense, $M | 21.6 | 18.8 | 25.2 | 30.6 | 23.8 | 21.5 |
| New customers acquired, thousands | 443 | 263 | 274 | 302 | 351 | 266 |
| Ad cost per new customer | $49 | $72 | $71 | $81 | $68 | $81 |
Two footnotes on that table, both from the filings. Fiscal 2024's sales bump is an acquisition, not a recovery: PetMed bought PetCareRx in April 2023 for $35.9 million net of cash. And in July 2024 the company loosened its own definition of a new customer, from someone with no order in thirty-six months to someone with no order in twelve. The recent counts are measured with the friendlier ruler, and they got worse anyway.
The structural break is fiscal 2022. New customers fell from 443,000 to 263,000 in one year, and the cost of each jumped from $49 to $72. That is the pandemic cohort lapsing and the digital auction repricing at the same time. The company's own fiscal 2026 explanation for the $81 figure is verbatim: "higher digital advertising costs, including increase cost-per-click rates during peak flea and tick season, as well as lower organic traffic."
One counter-signal belongs here. Fiscal 2025 actually improved, 351,000 new customers at $68, before fiscal 2026 worsened on deliberately reduced spend, $23.8 million down to $21.5 million. The 10-K attributes the new-order decline verbatim to "a strategic reduction in paid media advertising."
Now the arithmetic that turns a trend into a diagnosis. In fiscal 2026, PetMed spent $21.5 million on advertising and acquired 266,000 new customers, whose first orders produced $24.7 million in new-order sales. At the company's 28% gross margin, those first orders returned roughly $6.9 million in gross profit against the $21.5 million that bought them. Per customer: $81 to acquire, and a first order averaging $93 that returns about $26 of gross profit. The first order repays roughly a third of its own acquisition cost. The entire model is a bet on the reorder, and the reorder base is the cohort acquired years ago at $42.
The loss line needs one honest decomposition, because $57.3 million overstates the operating wound. Roughly half of it, $27.3 million, is a non-cash write-off, mostly the PetCareRx goodwill impairment. Another $4.5 million was the cost of an internal investigation we describe below, and $2.1 million was an inventory write-down on a wholesale deal that never happened. The remaining loss is an operating business that no longer covers its own overhead: adjusted EBITDA, the company's own preferred measure, swung from positive $0.7 million to negative $15.4 million in one year. Cash fell from $54.7 million to $21.4 million. The fiscal 2026 10-K says the conditions "raised substantial doubt about the Company's ability to continue as a going concern," then concludes the doubt is alleviated by a plan built on, among other things, "advertising and media spend optimization."
One more filing needs to be on the table. In April 2025, two anonymous reports arrived through the company's whistleblower hotline. The Audit Committee's investigation, conducted by outside counsel and forensic accountants, found that AutoShip shipments had been accelerated across quarter-ends, in violation of the company's own subscription terms, with about $1.2 million of revenue erroneously recorded in earlier quarters, and examined whether a $50 coupon launched ten days before fiscal year-end was, in the investigation's words, "motivated to any extent by its potential impact on Company KPIs regarding new customers." The dollar findings were small, and the committee found that the roughly 74 coupon orders with zero net sales did not have a material impact on the new-customer KPI. Over the same months, the board requested and accepted the resignations of the CEO and the CFO, and the chair of the Audit Committee resigned. Fiscal 2023 and 2024 were restated, and the fiscal 2025 annual report was filed six and a half months after the fiscal year ended. We make no accusation against any individual, and the filings themselves referred conduct questions to the board. What the episode documents is what the Audit Committee examined: whether the $50 coupon was motivated to any extent by its potential impact on Company KPIs. The KPI in question was new customers, the exact metric whose economics had broken.
The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, were $81 for the fiscal year ended March 31, 2026, compared to $68 for the fiscal year ended March 31, 2025. PetMed Express, Inc., Form 10-K for fiscal 2026, Management's Discussion and Analysis. Filed June 2, 2026.
Four public signals, captured July 7, 2026.
The brand that owned the category's front door now stands behind it. On a shared Google Trends scale over five years, searches for "1800petmeds" fell from a yearly average of 57.7 in 2021 to 13.1 in 2026. "Chewy pharmacy" rose from 20.3 to 42.7 over the same window and crossed above the full "petmeds" term for good around October 2024. Five years ago the toll-free brand out-drew "chewy pharmacy" three and a half to one. Today the relationship runs one to five the other way.
Residual demand still spells the category with their name. Rising demand names their competitors. The single most-searched refinement of "pet meds" over five years is still "1800 pet meds." But every fast-rising query names a different counter: "chewy pharmacy" up 200%, "publix pet meds" up 200%, "pet meds costco" up 70%, "pet meds near me" up 90%, and "lemonade pet insurance" up 2,000%. Buyers also increasingly search the medication, not the merchant: "simparica trio" queries are up over 1,000%, and the manufacturer's own site buys ads on category terms. The market is re-forming around platforms, retail counters, vets, and insurers, and the search data records the forwarding address.
PetMed ranks first for its founding query and pays for second place anyway. On "pet meds online," 1800petmeds.com is the top organic result and PetCareRx, which they also own, sits fifth. Above both, the first ad on the page belongs to Chewy: "Pet Medications - 50% Off 1st Rx Autoship Order." The second ad is PetMed's own, bidding on the exact phrase "pet meds online" from a campaign whose tracking tag, visible in the click URL, files the generic term under "Search-Brand... NewCustomers." The company is renting space on a page it already owns, one slot below the competitor that repriced the category. This is a single national capture and ad slots rotate, but the auction it documents is the $81 CAC, photographed.
The brand's own autocomplete is a service desk, not a storefront. Type "1800petmeds" into Google and the suggestions are dominated by account service and deal-hunting: login, in three variants, plus a vet login; coupon, promo code, discount code, and coupon 2026; phone number, fax number, customer service, reviews. One product name, one pharmacy query, and the site's own address round out the list. Almost every suggestion is an existing customer finding their account or pricing a reorder; almost nothing looks like a new buyer discovering a pharmacy. That matches the filings: 82.6% of fiscal 2026 revenue was reorders, and the 10-K blames part of the CAC increase on "lower organic traffic."
Two hypotheses the data killed. First, this is not a dying category: "pet pharmacy" searches are rising, medication-name searches are breaking out, and the category's new leaders are spending to win it. The demand PetMed built the category on still exists; it just checks out elsewhere. Second, this is not an awareness problem: the brand still tops the category's related searches and ranks first for its founding query. People know the name. Knowing the name no longer produces a customer at a price the first order can carry, and awareness was the one thing the ad budget was built to buy.
From the outside, this looks like a direct-response machine that outlived the environment that made its math work, run by an organization that kept reading the machine's gauges instead of the road.
The mechanism has three turns. First, the founding arbitrage closed. In 1996, "same medication, lower price, delivered" was a differentiating sentence that only PetMed was saying out loud. Today it is the table stakes of the category: Chewy's ad says 50% off, and Allivet's ad says up to 50% off. When your differentiator becomes the category's floor, continuing to advertise it means paying auction prices to say what every competitor on the page also says. The company's fiscal 2026 ad spend, 12% of sales, bought exactly that. The brand asset the whole machine was built to make ring is carried at $375,000, while $21.5 million a year now buys the clicks it no longer gets.
Second, the subscription changed who owns the reorder. PetMed's historical model owned the reorder by owning the relationship: the customer remembered the phone number, the postcard arrived, the refill happened. Autoship platforms moved the reorder into infrastructure. A Chewy customer does not re-decide her pharmacy every month; she decided once in 2021, and the decision now renews itself silently. This is why PetMed's reorder base, 82.6% of revenue, keeps shrinking in absolute dollars while its recurring share rises: the company is distilling toward its most loyal cohort while the pipeline that refills the cohort runs at a third of its old volume. Acquisition-led businesses age from the bottom.
Third, the organization metabolized the break as a numbers problem. The investigation record shows an organization whose attention was fixed on the new-customer figure: shipments accelerated across quarter-ends, a coupon examined for its effect on the KPI. Separately, in July 2024 the company had loosened its own definition of a new customer, and the counts worsened under the friendlier ruler anyway. We read all of this not as a morality tale but as an instrument reading. When a company's central marketing metric detaches from the economics underneath it, the pressure on the metric grows in proportion to what the market no longer volunteers. The investigation cost $4.5 million. The metric it orbited is the one in our table.
Underperforming a growing category, with acquisition messaging that has fully converged with the competitors who are winning: price, discount percentage, free shipping threshold, guarantee. Rocky Mountain Chocolate Factory had a message and would not pay for a transmitter. PetMed pays for the transmitter at full auction price and sends the same message as everyone else on the page. Incremental optimization inside the current frame is spending money to lose more slowly. The frame has to change.
What we cannot see from outside, and say so plainly: gross media spend by channel, and how much of the $21.5 million is brand defense versus prospecting; cohort retention curves, the single number that decides whether the $81 is madness or patience; contribution margin by channel and by drug class; the real state of the PetCareRx integration; and the terms of the Vetster partnership and any vet-channel pilots. One disclosed fact belongs alongside those unknowns: in December 2025 the company received two unsolicited acquisition proposals at $4.00 to $4.25 per share, which the board evaluated and determined not to proceed with, per the fiscal 2026 10-K. Any of the unknowns could revise the diagnosis. That is what inside data is for.
These are hypotheses, not recommendations. Each comes with the test that would confirm or kill it.
The one sentence on PetMed's page that Chewy cannot say is "America's first online pet pharmacy." The company's own strategy language in the fiscal 2026 10-K already points here, verbatim: "transitioning from a traditional e-commerce provider to a best-in-class pharmacy provider." The ads have not made the turn; the live creative still leads with best prices and price match. Pharmacists and technicians "licensed across all fifty states," in the filing's words, and a pharmacy that has dispensed pet medications since 1996: that is a trust story aimed at the exact anxieties that keep first-time buyers at the vet's counter.
The buyer's trust follows the prescriber, and the simulated panel below found legitimacy and verification, not price, to be the highest-friction objections. PetMed's filings again already name the direction: offering its "proprietary pharmacy fulfillment and licensing capabilities to strategic partners," and, verbatim, "we intend to partner with veterinarians and clinics to provide integrated pharmacy fulfillment services." That is a B2B repositioning of a B2C asset: the pharmacy stops being the vet's competitor and becomes the vet's back office, against the incumbents that already sit inside clinic workflows.
The fiscal record suggests the organization steers by a number whose economics broke in fiscal 2022, and the governance record shows the board treating that number's integrity as a board-level matter. The repositioning here is internal: measure and compensate on twelve-month cohort gross profit against acquisition cost, by channel, and let the $81 defend itself or die by cohort.
Before publishing, we ran the positioning question past a synthetic buyer panel: ten constructed personas of dog and cat medication buyers, deliberately spanning the migration this report describes, from a Chewy autoship loyalist and a vet-portal-only skeptic to a phone-order boomer who has bought from 1-800-PetMeds for years, a coupon-hunting multi-pet owner, and a first-time millennial buyer who has never heard the jingle. This is simulated data. It is not customer research, and no PetMed customer data exists in it. We use it the way an architect uses a wind model: cheap directional pressure-testing before anyone builds anything.
The incumbent message finished last. The two messages that beat it are the two things the category's new owners already sell, which is the Bear Trap photographed from inside the panel: the company's paid voice is the weakest available version of a claim it has unusual standing to make. The margin is honest, though: 4.8 points top to bottom, and the top two are within noise of each other, so the panel picks a direction, not a winner. The price message still won the coupon-hunter persona outright, and she is exactly the customer the CAC table prices: zero loyalty by construction, $81 to acquire, hers until the next promo code.
Cohort retention curves first, because they decide everything: what a fiscal 2024 customer acquired at $81 actually returned by month twelve, against the fiscal 2019 customer acquired at $47. Channel-level media spend and CAC, separating brand defense from prospecting. Contribution margin by drug class, since chronic medications and preventatives age differently with the pet. The PetCareRx integration state and what $35.9 million actually bought. The vet-channel work: clinics approached, scripts routed, the unit economics of clinic fulfillment, and the terms of the Vetster partnership. And the AutoShip cohort's true churn, the number the accelerated-shipment episode shows deserves a clean, audited read.
That is a two-week diagnostic, not a two-year transformation.